OBJECTIVES: The management of hemophilia when patients develop inhibitors is particularly complex and costly. Although the advances of modern technologies, no agreement still exists on how to optimally treat these patients. Treatment of haemophilia is result of interactions between patients, physicians, pharmacists and budget holders, each carrying their own set of preferences. This study was conducted to evaluate preferences toward possible coagulation factor concentrates used in patients with inhibitors from a sample of patients (or caregivers of pediatric patients), physicians specialist in hemophilia care, pharmacists with experience in storing/delivering coagulation factor concentrates. METHODS: A Discrete Choice Experiment was conducted, by describing possible products with 7 attributes selected from a previous pilot study: “viral safety”, “risk of anamnestic response”, “possibility of undergoing major surgery”, “frequency of infusions in prophylaxis”, “number of injections to stop bleeding”, “time to stop bleeding”, “time to pain recovery”. Cost, expressed as increase of health care taxes, was added to estimate willingness to pay towards these attributes. The respondents were asked to choose among 16 pair-wise choice sets. A random-effect logit model was used to analyse the data. RESULTS: Thirty-seven patients or proxies (their caregivers), 39 physicians, 25 pharmacists were interviewed. All the patients had severe hemophilia A, historical median (min-max) peak titre=164 (5-16,400) BU/mL. Among all the respondents, the hypothesized direction of preferences was confirmed (e.g. lower risk of infections was preferred than higher risk) and the importance of preferences was statistically significant: p-values<0.01 for every attribute. The 3 subgroups anyway reported different preferences in some attributes. CONCLUSION: this study revealed patients/caregivers', physicians' and pharmacists' preferences towards the products used to treat hemophilic patients with inhibitors. Understanding the preferences from different perspectives can be useful to optimize the benefits deriving from the decisions on treatments for hemophilic patients with inhibitors.